Preferred Label : Daclizumab;
MeSH definition : An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin
G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used
in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.;
MeSH synonym : Dacliximab;
MeSH hyponym : Ro 24 7375; Ro 247375; Ro-24-7375;
MeSH Related Number : 152923-56-3 (Daclizumab);
Wikipedia link : https://en.wikipedia.org/wiki/Daclizumab;
UNII : CUJ2MVI71Y;
Origin ID : D000077561;
UMLS CUI : C0663182;
ATC code(s)
- Allowable qualifiers
- MeSH indexing information
- Pharmacological action(s)
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- Validated automatic mappings to BTNT
An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin
G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used
in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.
https://medicalforum.ch/fr/detail/doi/fms.2019.03439/
https://doi.org/10.4414/fms.2019.03439
2019
false
false
false
Switzerland
case reports
immune system
multiple sclerosis, relapsing-remitting
Drug-Related side effects and adverse reactions
exanthema
Chemical and Drug Induced Liver Injury
fever
journal article
Daclizumab
---
ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/66214a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
Safety-Based drug withdrawals
risk
encephalitis
daclizumab
meningoencephalitis
meningoencephalitis
encephalitis
multiple sclerosis
guidelines for drug use
popular works
Chemical and Drug Induced Liver Injury
Zinbryta
Daclizumab
---
https://www.has-sante.fr/portail/jcms/c_2825864/fr/zinbryta
2018
false
false
false
false
France
French
evaluation of the transparency committee
daclizumab
treatment outcome
immunosuppressive agents
immunosuppressive agents
injections, subcutaneous
multiple sclerosis
Daclizumab
Daclizumab
---
http://www.has-sante.fr/portail/jcms/c_2742059/fr/zinbryta
http://www.has-sante.fr/portail/jcms/c_2742059/fr/zinbryta-daclizumab-immunosuppresseur
2017
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
multiple sclerosis
daclizumab
Product containing daclizumab (medicinal product)
injections, subcutaneous
Pre-filled Pen Syringe
Prefilled Syringe Dosage Form
adult
insurance, health, reimbursement
immunosuppressive agents
immunosuppressive agents
guidelines for drug use
Daclizumab
Daclizumab
---
Summary Basis of Decision (SBD) for Zinbryta
Daclizumab beta 150 mg/mL, solution, subcutaneous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00342
2017
false
false
false
Canada
French
English
drug information
multiple sclerosis
antibodies, monoclonal, humanized
immunoglobulin G
Daclizumab
---
https://www.ema.europa.eu/medicines/human/EPAR/Zinbryta
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
product surveillance, postmarketing
drug approval
europe
daclizumab
Product containing daclizumab (medicinal product)
adult
multiple sclerosis, relapsing-remitting
injections, subcutaneous
self administration
treatment outcome
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Daclizumab
Daclizumab
---
http://www.cochrane.org/fr/CD008127
http://www.cochrane.org/fr/CD008127/le-daclizumab-zenapax-est-un-medicament-immunosuppresseur-dont-lefficacite-chez-les-patients-atteints-de-sclerose-en-plaques-sep-merite-quelque-attention
2012
false
true
false
United Kingdom
France
immunosuppressive agents
immunosuppressive agents
review of literature
french abstract
multiple sclerosis, relapsing-remitting
Daclizumab
Daclizumab
---
https://www.ema.europa.eu/medicines/human/EPAR/Zenapax
2008
false
United Kingdom
French
English
syndication feed
corticosteroid therapy
Daclizumab
immunosuppressive agents
graft rejection
kidney transplantation
transplantation, homologous
drug therapy, combination
adult
child
immunosuppressive agents
treatment outcome
Interleukin-2
receptors, interleukin-2
drug evaluation
daclizumab
drug evaluation
summary of product characteristics
package leaflet
Daclizumab
---
